Novartis beats Q4 earnings consensus

Novartis beats Q4 earnings consensus as drug sales surge
Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded forecasts. Fourth-quarter net income,
Novartis: Q4 Earnings Snapshot
BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company said it had net income of $1.41. Earnings, adjusted for non-recurring costs, came to $1.98 per share.
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.
Novartis handily beats Q4 earnings consensus
Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established heart failure drug Entresto and multiple sclerosis drug Kesimpta. Fourth-quarter net income,
Novartis Expects Further Profit, Growth After Key Drugs Boost Sales
Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its key drugs.
Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales
Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance.
Novartis Expects Further Profit, Sales Growth Despite Competition Threat
The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...
Novartis CEO says U.S. exit from global health programmes to affect millions
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
FierceBiotech3h
Novartis missed the PD-1 boat. Will it catch the bispecific wave?
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...
Novartis Q4 Profit Down, Core EPS Beat Market; Lifts Dividend; Sees Growth In FY25
Swiss drug major Novartis AG (NVS) reported Friday that its fourth-quarter net income plunged to $2.82 billion from last year's $8.48 ...
FiercePharma2d
Novartis' first Super Bowl ad aims to 'create a movement' with breast cancer awareness blitz
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...
manilatimes4h
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Sales growth driven by continued strong performance from Entresto (+31% cc), Cosentyx (+25% cc), Kesimpta (+49% cc), Kisqali (+49% cc), Pluvicto (+42% cc) and Leqvio (+114% cc) Core operating income ...
Novartis AG (NOVN) Gets a Hold from Jefferies
Jefferies analyst Peter Welford maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
Swissinfo3h
Novartis forecasts profit gains despite copycat competition
Novartis said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug.
MM&M2d
Novartis taps Hailee Steinfeld, Wanda Sykes for breast cancer Super Bowl ad
In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...
Bernstein Reaffirms Their Buy Rating on Novartis AG (NOVN)
Bernstein analyst Florent Cespedes maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...